Carolyn Tang

Ms Tang is an attorney with broad expertise in transactions, intellectual property, securities and corporate governance (US and Europe). Prior to joining Arcus, Carolyn was responsible for strategic transactions, securities and corporate governance at Medivation, until its acquisition by Pfizer. Prior to Medivation, Ms Tang held positions of increasing responsibility at InterMune, where she oversaw the company’s global IP portfolio and supported the approval and commercialization of Esbriet® as a treatment for idiopathic pulmonary fibrosis in the EU, Canada, and US. She helped establish and administer InterMune’s European subsidiaries and assisted in public offerings of common stock and convertible senior notes raising nearly $850 million in the 4 years prior to the company’s acquisition by Roche.